March 25 (Reuters) - Vanda Pharmaceuticals Inc :
* Reports successful completion of pre-NDA meeting with FDA on tasimelteon for
the treatment of non-24-hour disorder in the totally blind
* FDA confirmed that efficacy and safety data to be submitted in tasimelteon
NDA for non-24 is adequate to support filing
* Says is targeting an NDA submission for tasimelteon in mid-2013.
* Source text * Further company coverage
((Bangalore Newsroom; +1 646 223 8780))
0 comments:
Post a Comment